Biswas G, Parikh P M, Nair R, Bhagwat R, Bakshi A, Prabhash K, Vora A, Gupta S, Pai V R, Menon H, Sastry P S R K
Department of Medical Oncology, Tata Memorial Hospital, Parel, Mumbai, India.
J Assoc Physicians India. 2006 Jan;54:29-33.
Rituximab has been used extensively in lymphoproliferative disorders. We evaluated the results of 64 consecutive patients treated between 2001 and 2004 at our institution. This included 54 males and 10 females. The median age was 54 years (range 17 to 85 years). One-fourth of patients were above 60 years. The histology was aggressive NHL in 35, indolent NHL in 22 and 7 cases were diagnosed as CLL. Among NHL, sixteen were in early stage (I/II) and the remaining forty-one were in advanced stage (III/IV) of disease. B symptoms were present in 47% of cases. A total of 33 were de novo cases and 31 were previously treated. Rituximab monotherapy was used in 17 cases. Rituximab was used in combination with chemotherapy in the other 47 cases. Infusional toxicity included anaphylaxis in one, hypotension in one and minor infusional reactions in four others. The patient who developed anaphylaxis required discontinuation of further Rituximab. Growth factors were used in 25 patients. Febrile neutropenia occurred in 19 patients. The overall RR (CR + PR) was 72%. One patient had stable disease and progressive disease was documented in 17 patients. A total of seven patients died, three due to progressive disease, three due to chemotherapy related toxicity and one due to an unrelated cause. We conclude that Rituximab is a valuable addition to the treatment armamentarium of lymphoproliferative disorders.
利妥昔单抗已广泛应用于淋巴增殖性疾病。我们评估了2001年至2004年在我们机构接受治疗的64例连续患者的结果。其中包括54名男性和10名女性。中位年龄为54岁（范围17至85岁）。四分之一的患者年龄在60岁以上。组织学类型为侵袭性非霍奇金淋巴瘤（NHL）35例，惰性NHL 22例，7例诊断为慢性淋巴细胞白血病（CLL）。在NHL中，16例处于疾病早期（I/II期），其余41例处于疾病晚期（III/IV期）。47%的病例出现B症状。共有33例为初发病例，31例曾接受过治疗。17例使用利妥昔单抗单药治疗。其他47例使用利妥昔单抗联合化疗。输注毒性包括1例过敏反应、1例低血压和另外4例轻微输注反应。发生过敏反应的患者需要停止进一步使用利妥昔单抗。25例患者使用了生长因子。19例患者发生发热性中性粒细胞减少。总体缓解率（完全缓解+部分缓解）为72%。1例患者病情稳定，17例记录为疾病进展。共有7例患者死亡，3例死于疾病进展，3例死于化疗相关毒性，1例死于无关原因。我们得出结论，利妥昔单抗是淋巴增殖性疾病治疗手段中的一项有价值的补充。
